Cell-based drug delivery for improving antiretroviral therapeutic outcomes

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

During the past decade, our laboratories pioneered the use of monocyte-macrophages as Trojan horses for the uptake, trafficking, and delivery of nanoformulated antiretroviral therapy (nanoART) to improve drug delivery to tissue, cell, and subcellular sites of human immunodeficiency virus infections. Particles were manufactured with excipients and coated with sugars or peptides to facilitate particle uptake and sequestration in mononuclear phagocytes. Particles housed as cellular depots in recycling endosomes and free bioactive medicines dissociated from particles were released over periods of days to weeks. This enabled long-lived drug tissue reservoirs where peripheral monocytes and tissue macrophages activated by the nanoparticles are able to sequester ART for periods of weeks and longer. Indeed, following parenteral injection of the particles high concentrations of drug are found in the reticuloendothelial system with limited systemic toxicities enabling prolonged drug-dosing intervals. Target coating of the particles further facilitated pharmacokinetic and pharmacodynamics improvements over native or naked uncoated particle drug administrations, especially in reaching reservoirs of viral infection, such as the brain, gut, and lymphoid organs. The future of such therapies towards improving drug compliance, diminishing viral resistance, and facilitating residual virus reductions is timely and important and expanded upon within the current review.

Original languageEnglish (US)
Title of host publicationNeuroinflammation and Neurodegeneration
PublisherSpringer New York
Pages529-546
Number of pages18
ISBN (Electronic)9781493910717
ISBN (Print)1493910701, 9781493910700
DOIs
StatePublished - Apr 1 2014

Fingerprint

Pharmaceutical Preparations
Virus Diseases
Monocytes
Therapeutics
Macrophages
Mononuclear Phagocyte System
Excipients
Endosomes
Phagocytes
Nanoparticles
Pharmacokinetics
HIV
Viruses
Peptides
Injections
Brain

Keywords

  • Antiretroviral Therapeutics
  • Cell-based drug delivery
  • HIV
  • Humanized mice models
  • Macrophage
  • NanoART
  • Nanoparticle

ASJC Scopus subject areas

  • Medicine(all)
  • Neuroscience(all)

Cite this

Cell-based drug delivery for improving antiretroviral therapeutic outcomes. / McMillan, JoEllyn M; Gendelman, Howard Eliot.

Neuroinflammation and Neurodegeneration. Springer New York, 2014. p. 529-546.

Research output: Chapter in Book/Report/Conference proceedingChapter

McMillan, JoEllyn M ; Gendelman, Howard Eliot. / Cell-based drug delivery for improving antiretroviral therapeutic outcomes. Neuroinflammation and Neurodegeneration. Springer New York, 2014. pp. 529-546
@inbook{0bf3a2b8b92a492b9457c2219864993a,
title = "Cell-based drug delivery for improving antiretroviral therapeutic outcomes",
abstract = "During the past decade, our laboratories pioneered the use of monocyte-macrophages as Trojan horses for the uptake, trafficking, and delivery of nanoformulated antiretroviral therapy (nanoART) to improve drug delivery to tissue, cell, and subcellular sites of human immunodeficiency virus infections. Particles were manufactured with excipients and coated with sugars or peptides to facilitate particle uptake and sequestration in mononuclear phagocytes. Particles housed as cellular depots in recycling endosomes and free bioactive medicines dissociated from particles were released over periods of days to weeks. This enabled long-lived drug tissue reservoirs where peripheral monocytes and tissue macrophages activated by the nanoparticles are able to sequester ART for periods of weeks and longer. Indeed, following parenteral injection of the particles high concentrations of drug are found in the reticuloendothelial system with limited systemic toxicities enabling prolonged drug-dosing intervals. Target coating of the particles further facilitated pharmacokinetic and pharmacodynamics improvements over native or naked uncoated particle drug administrations, especially in reaching reservoirs of viral infection, such as the brain, gut, and lymphoid organs. The future of such therapies towards improving drug compliance, diminishing viral resistance, and facilitating residual virus reductions is timely and important and expanded upon within the current review.",
keywords = "Antiretroviral Therapeutics, Cell-based drug delivery, HIV, Humanized mice models, Macrophage, NanoART, Nanoparticle",
author = "McMillan, {JoEllyn M} and Gendelman, {Howard Eliot}",
year = "2014",
month = "4",
day = "1",
doi = "10.1007/978-1-4939-1071-7_25",
language = "English (US)",
isbn = "1493910701",
pages = "529--546",
booktitle = "Neuroinflammation and Neurodegeneration",
publisher = "Springer New York",

}

TY - CHAP

T1 - Cell-based drug delivery for improving antiretroviral therapeutic outcomes

AU - McMillan, JoEllyn M

AU - Gendelman, Howard Eliot

PY - 2014/4/1

Y1 - 2014/4/1

N2 - During the past decade, our laboratories pioneered the use of monocyte-macrophages as Trojan horses for the uptake, trafficking, and delivery of nanoformulated antiretroviral therapy (nanoART) to improve drug delivery to tissue, cell, and subcellular sites of human immunodeficiency virus infections. Particles were manufactured with excipients and coated with sugars or peptides to facilitate particle uptake and sequestration in mononuclear phagocytes. Particles housed as cellular depots in recycling endosomes and free bioactive medicines dissociated from particles were released over periods of days to weeks. This enabled long-lived drug tissue reservoirs where peripheral monocytes and tissue macrophages activated by the nanoparticles are able to sequester ART for periods of weeks and longer. Indeed, following parenteral injection of the particles high concentrations of drug are found in the reticuloendothelial system with limited systemic toxicities enabling prolonged drug-dosing intervals. Target coating of the particles further facilitated pharmacokinetic and pharmacodynamics improvements over native or naked uncoated particle drug administrations, especially in reaching reservoirs of viral infection, such as the brain, gut, and lymphoid organs. The future of such therapies towards improving drug compliance, diminishing viral resistance, and facilitating residual virus reductions is timely and important and expanded upon within the current review.

AB - During the past decade, our laboratories pioneered the use of monocyte-macrophages as Trojan horses for the uptake, trafficking, and delivery of nanoformulated antiretroviral therapy (nanoART) to improve drug delivery to tissue, cell, and subcellular sites of human immunodeficiency virus infections. Particles were manufactured with excipients and coated with sugars or peptides to facilitate particle uptake and sequestration in mononuclear phagocytes. Particles housed as cellular depots in recycling endosomes and free bioactive medicines dissociated from particles were released over periods of days to weeks. This enabled long-lived drug tissue reservoirs where peripheral monocytes and tissue macrophages activated by the nanoparticles are able to sequester ART for periods of weeks and longer. Indeed, following parenteral injection of the particles high concentrations of drug are found in the reticuloendothelial system with limited systemic toxicities enabling prolonged drug-dosing intervals. Target coating of the particles further facilitated pharmacokinetic and pharmacodynamics improvements over native or naked uncoated particle drug administrations, especially in reaching reservoirs of viral infection, such as the brain, gut, and lymphoid organs. The future of such therapies towards improving drug compliance, diminishing viral resistance, and facilitating residual virus reductions is timely and important and expanded upon within the current review.

KW - Antiretroviral Therapeutics

KW - Cell-based drug delivery

KW - HIV

KW - Humanized mice models

KW - Macrophage

KW - NanoART

KW - Nanoparticle

UR - http://www.scopus.com/inward/record.url?scp=84929871050&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84929871050&partnerID=8YFLogxK

U2 - 10.1007/978-1-4939-1071-7_25

DO - 10.1007/978-1-4939-1071-7_25

M3 - Chapter

SN - 1493910701

SN - 9781493910700

SP - 529

EP - 546

BT - Neuroinflammation and Neurodegeneration

PB - Springer New York

ER -